Christopher Semsarian

Christopher Semsarian

Auto-generated profile, based on publicly available information

Christopher Semsarian

Agnes Ginges Centre for Molecular Cardiology at Centenary Institute (C.S.), The University of Sydney, New South Wales, Australia

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2021 in Circulation
Verified
Journal Article
Open access
PDF file
EJElizabeth Jordan
Elizabeth Jordan
LPLaiken Peterson
Laiken Peterson
TATomohiko Ai
Tomohiko Ai
BABabken Asatryan
Babken Asatryan
LBLucas Bronicki
Lucas Bronicki
RHRay E. Hershberger
Ray E. Hershberger
Background: Each of the cardiomyopathies, classically categorized as hypertrophic cardiomyopathy, dilated cardiomyopathy (DCM), and arrhythmogenic right ventricular cardiomyopathy, has a signature genetic theme. Hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy are largely understood as genetic diseases of sarcomere or desmosome proteins, respectively. In contrast, >250 genes spanning >10 gene ontologies have been implicated in DCM, representing a complex and diverse genetic architecture. To clarify this, a systematic curation of evidence to establish the relationship of genes with DCM was conducted. Methods: An international panel with clinical and scientific expertise in DCM genetics evaluated evidence supporting monogenic relationships of genes with idiopathic DCM. The panel used the Clinical Genome Resource semiquantitative gene-disease clinical validity classification framework with modifications for DCM genetics to classify genes into categories on the basis of the strength of currently available evidence. Representation of DCM genes on clinically available genetic testing panels was evaluated. Results: Fifty-one genes with human genetic evidence were curated. Twelve genes (23%) from 8 gene ontologies were classified as having definitive ( BAG3 , DES , FLNC , LMNA , MYH7 , PLN , RBM20 , SCN5A , TNNC1 , TNNT2 , TTN ) or strong ( DSP ) evidence. Seven genes (14%; ACTC1 , ACTN2 , JPH2 , NEXN , TNNI3 , TPM1 , VCL ) including 2 additional ontologies were classified as moderate evidence; these genes are likely to emerge as strong or definitive with additional evidence. Of these 19 genes, 6 were similarly classified for hypertrophic cardiomyopathy and 3 for arrhythmogenic right ventricular cardiomyopathy. Of the remaining 32 genes (63%), 25 (49%) had limited evidence, 4 (8%) were disputed, 2 (4%) had no disease relationship, and 1 (2%) was supported by animal model data only. Of the 16 evaluated clinical genetic testing panels, most definitive genes were included, but panels also included numerous genes with minimal human evidence. Conclusions: In the curation of 51 genes, 19 had high evidence (12 definitive/strong, 7 moderate). It is notable that these 19 genes explain only a minority of cases, leaving the remainder of DCM genetic architecture incompletely addressed. Clinical genetic testing panels include most high-evidence genes; however, genes lacking robust evidence are also commonly included. We recommend that high-evidence DCM genes be used for clinical practice and that caution be exercised in the interpretation of variants in variable-evidence DCM genes.

4 April 2022 in EP Europace
Verified
Journal Article
Open access
AWArthur A M Wilde
Arthur A M Wilde
CSChristopher Semsarian
Christopher Semsarian
MMManlio F. Márquez
Manlio F. Márquez
ASAlireza Sepehri Shamloo
Alireza Sepehri Shamloo
MAMichael J Ackerman
Michael J Ackerman
TDThomas Deneke
Thomas Deneke

1 August 2020 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
PDF file
KMKiran Musunuru
Kiran Musunuru
RHRay E. Hershberger
Ray E. Hershberger
SDSharlene M. Day
Sharlene M. Day
NKN. Jennifer Klinedinst
N. Jennifer Klinedinst
ALAndrew Landstrom
Andrew Landstrom
CCCouncil On Clinical Cardiology
Council On Clinical Cardiology
Advances in human genetics are improving the understanding of a variety of inherited cardiovascular diseases, including cardiomyopathies, arrhythmic disorders, vascular disorders, and lipid disorders such as familial hypercholesterolemia. However, not all cardiovascular practitioners are fully aware of the utility and potential pitfalls of incorporating genetic test results into the care of patients and their families. This statement summarizes current best practices with respect to genetic testing and its implications for the management of inherited cardiovascular diseases.

24 December 2015 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
RBRichard D. Bagnall
Richard D. Bagnall
DCDouglas E. Crompton
Douglas E. Crompton
SPSlavé Petrovski
Slavé Petrovski
LLLien Lam
Lien Lam
CCCarina Cutmore
Carina Cutmore
CSChristopher Semsarian
Christopher Semsarian

11 March 2015 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
CSChristopher Semsarian
Christopher Semsarian
JIJodie Ingles
Jodie Ingles
AWArthur A.M. Wilde
Arthur A.M. Wilde
The sudden death of a young, apparently fit and healthy person is amongst the most challenging scenarios in clinical medicine. Sudden cardiac death (SCD) is a devastating and tragic outcome of a number of underlying cardiovascular diseases. While coronary artery disease and acute myocardial infarction are the most common causes of SCD in older populations, genetic (inherited) cardiac disorders comprise a substantial proportion of SCD cases aged 40 years and less. This includes the primary arrhythmogenic disorders such as long QT syndromes and inherited cardiomyopathies, namely hypertrophic cardiomyopathy. In up to 30% of young SCD, no cause of death is identified at postmortem, so-called autopsy-negative or sudden arrhythmic death syndrome (SADS). Management of families following SCD begins with a concerted effort to identify the cause of death in the decedent, based on either premorbid clinical details or the pathological findings at postmortem. Where no cause of death is identified, genetic testing of deoxyribonucleic acid extracted from postmortem blood (the molecular autopsy) may identify a cause of death in up to 30% of SADS cases. Irrespective of the genetic testing considerations, all families in which a sudden unexplained death has occurred require targeted and standardized clinical testing in an attempt to identify relatives who may be at-risk of having the same inherited heart disease and therefore also predisposed to an increased risk of SCD. Optimal care of SCD families therefore requires dedicated and appropriately trained staff in the setting of a specialized multidisciplinary cardiac genetic clinic.

4 April 2022 in Heart Rhythm
Verified
Journal Article
Open access
AWArthur A.M. Wilde
Arthur A.M. Wilde
CSChristopher Semsarian
Christopher Semsarian
MMManlio F. Márquez
Manlio F. Márquez
ASAlireza Sepehri Shamloo
Alireza Sepehri Shamloo
MAMichael J. Ackerman
Michael J. Ackerman
TDThomas Deneke
Thomas Deneke